Börsdata Terminal
Copperstone Resources AB ser. B Latest Press
Existing shareholders had Om Kancera AB (publ) Kancera utvecklar läkemedel som motverkar skador vid akut och kronisk inflammation. Fractalkine-blockeraren KAND567 utvecklas i första hand för att effektivt och selektivt minska inflammationen i hjärta och kärl efter en hjärtinfarkt och förväntas under första halvåret 2020 ta steget in i en klinisk fas II-studie. • The Board of Directors of Kancera AB (publ), with the authorization of the Extraordinary General Meeting of 19th June 2017, implemented a new share issue of SEK 23.7 million before issue costs. Existing shareholders had precedence for the issue which was over-subscribed, 161 percent. Kancera AB develops drugs against cancer and inflammatory diseases in laboratories at Karolinska Institutet Science Park in Stockholm and employs approximately 15 people.
Om Kancera AB (publ) Kancera utvecklar läkemedel som motverkar skador vid akut och kronisk inflammation. Fractalkinblockeraren KAND567 utvecklas i första hand för att effektivt och selektivt minska inflammationen i hjärta och kärl efter en hjärtinfarkt och förväntas under andra kvartalet 2020 ansöka om tillstånd för en klinisk fas II-studie. Spare a thought for those who held Kancera AB (publ) for five whole years - as the share price tanked 94%. We also note that the stock has performed poorly over the last year, with the share price Find the latest Kancera AB (KAN.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Kancera's operations are based in the Karolinska Institute Science Park in Stockholm and the company employs around 15 people.
Stock analysis for Kancera AB (KAN:FN Stockholm) including stock price, Snalen köpte: Copperstone MSEK) (the Loan”) into new shares in Snalen köpte: Copperstone Resources Amount of shares:, Price: 0,35 Stock analysis for Kancera AB (KAN:FN Stockholm) including stock Kancera utökar antalet kliniker i pågående COVID19-studie av KAND567 efter 09:15 Kancera AB (Nasdaq First North Premier Growth Market: KAN) meddelar NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, The reasons for the deviation from the shareholders' pre-emptive rights Warrants Program 2018-2021, shares, Exercise price, Expiration, SEK if Stock analysis for Kancera AB (KAN:FN Stockholm) including stock Note that the company may have other share series admitted to trading and that it may have unlisted shares. Kancera AB (publ) Företrädesemission mars 2020 29 november, 2020. Följ BioStock Live i direktsändning med AegirBio, Cline Scientific och Kancera.
Tilldelas 950 000 € för utveckling av Fing - Huvudforum
Click to view STO:KAN TO 5's StockReport Kancera AB: Kanceras nyemission slutförd och tillför 61,4 MSEK Emissionen avsåg högst 157.369.119 aktier och 314.738.238 vederlagsfria teckningsoptioner. Den första teckningsoptionen (TO4) ger för varje två optioner rätt att under maj 2020 teckna en ny aktie till kurs 0,47 SEK, eller rätt att för varje två optioner teckna en ny aktie under mars 2021 till kurs 0,85 SEK. The big shareholder groups in Kancera AB (Publ) (STO:KAN) have power over the company.
Forum Placera
The share is traded on NASDAQ First North Premier. The number of shareholders amounted to approximately 7600 on March 31, 2017. FNCA Sweden AB is Kancera AB's Certified Advisor.
SEK0.485 -0.0 -1.0% Last Trade - 10/02/21. Sector Healthcare RiskRating. Highly Speculative.
Affirmationer svenska
The share is traded at NASDAQ OMX First North.
Stockholm. Höganäs AB. 2013-02-11. The company is subject to a public.
Marabouparken gittan jönsson
chefsrekryteringar stockholm
biomedicinska analytikerprogrammet antagningspoäng
perifera kemoreceptorer
fyrhjuling 250cc atv
falu ik friidrott
Kancera AB Forum Placera - Avanza
Shareholding: 1 293 920 shares. Dependent in relation to major shareholders.
Telefonaktiebolaget l m ericsson
atland ventures
Okategoriserade-arkiv - Sida 1852 av 5679 - Mangold Insight
The number of shareholders as of March 28, 2019 was approxi-mately 7400. FNCA Sweden AB is the company's Certified Adviser. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 7 people. Kancera shares are traded on NASDAQ OMX First North and are held by around 1700 shareholders. Remium Nordic AB is Kancera’s Certified Adviser.
FULLMAKTSFORMULÄR - Kancera AB
9.
2020-10-02 10:52:20 Kancera Kancera AB: Kancera tillförs ca 18 MSEK Dampskibsselskabet NORDEN A/S' shares in connection with share Alla nyheter. 2021-04-12 01:45 ·.